Hemogenyx Pharmaceuticals Plc (HOPHF)
USD 1.24
(3000.0%)
USD 1.24
(3000.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.69 Million GBP | 90.8% |
| 2022 | 890.07 Thousand GBP | 113.03% |
| 2021 | -6.83 Million GBP | -3609.03% |
| 2020 | -184.16 Thousand GBP | -124.28% |
| 2019 | 758.57 Thousand GBP | 228.66% |
| 2018 | -589.6 Thousand GBP | 68.58% |
| 2017 | -1.87 Million GBP | -152.01% |
| 2016 | -744.66 Thousand GBP | -483.83% |
| 2015 | 194 Thousand GBP | 3214.09% |
| 2014 | -6230.00 GBP | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -1.64 Million GBP | -196.73% |
| 2024 Q2 | -1.64 Million GBP | 169.48% |
| 2023 Q4 | 1.69 Million GBP | 19.16% |
| 2023 Q2 | 180.2 Thousand GBP | 167.33% |
| 2023 Q1 | -267.63 Thousand GBP | -130.07% |
| 2023 Q3 | 1.42 Million GBP | 690.89% |
| 2023 FY | 1.69 Million GBP | 90.8% |
| 2022 Q1 | -5.79 Million GBP | 15.1% |
| 2022 Q2 | -5.79 Million GBP | 0.0% |
| 2022 Q4 | 890.07 Thousand GBP | 56.73% |
| 2022 FY | 890.07 Thousand GBP | 113.03% |
| 2022 Q3 | 567.92 Thousand GBP | 109.79% |
| 2021 Q1 | -9.05 Million GBP | -4819.09% |
| 2021 FY | -6.83 Million GBP | -3609.03% |
| 2021 Q4 | -6.83 Million GBP | 0.15% |
| 2021 Q3 | -6.84 Million GBP | 24.24% |
| 2021 Q2 | -9.03 Million GBP | 0.32% |
| 2020 Q3 | -222.89 Thousand GBP | 86.13% |
| 2020 Q4 | -184.16 Thousand GBP | 17.37% |
| 2020 Q1 | -1.65 Million GBP | -317.85% |
| 2020 FY | -184.16 Thousand GBP | -124.28% |
| 2020 Q2 | -1.6 Million GBP | 2.76% |
| 2019 Q3 | 718.68 Thousand GBP | 752.82% |
| 2019 Q4 | 758.57 Thousand GBP | 5.55% |
| 2019 Q2 | 84.27 Thousand GBP | 0.0% |
| 2019 FY | 758.57 Thousand GBP | 228.66% |
| 2019 Q1 | 84.27 Thousand GBP | 114.29% |
| 2018 Q1 | -1.24 Million GBP | 33.77% |
| 2018 Q4 | -589.6 Thousand GBP | 0.0% |
| 2018 FY | -589.6 Thousand GBP | 68.58% |
| 2018 Q3 | -589.6 Thousand GBP | 52.56% |
| 2018 Q2 | -1.24 Million GBP | 0.0% |
| 2017 Q1 | 87.22 Thousand GBP | 111.73% |
| 2017 FY | -1.87 Million GBP | -152.01% |
| 2017 Q2 | -929.27 Thousand GBP | -1165.4% |
| 2017 Q3 | -1.87 Million GBP | -101.95% |
| 2017 Q4 | -1.87 Million GBP | 0.0% |
| 2016 Q4 | -743.88 Thousand GBP | 0.0% |
| 2016 FY | -744.66 Thousand GBP | -483.83% |
| 2016 Q2 | -1.21 Million GBP | 0.0% |
| 2015 FY | 194 Thousand GBP | 3214.09% |
| 2014 FY | -6230.00 GBP | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bioxytran, Inc. | 1.89 Million USD | 10.565% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 89.226% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -322.618% |
| SQZ Biotechnologies Company | -36.23 Million USD | 104.686% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 24.259% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 96.031% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 126.938% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -83.166% |
| Marizyme, Inc. | 18.56 Million USD | 90.854% |
| Genus plc | 190.6 Million USD | 99.109% |
| Pharming Group N.V. | 109.8 Million USD | 98.453% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -97.42% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -39.905% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -149.748% |
| ContraFect Corporation | -6.02 Million USD | 128.183% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -46.983% |
| IMV Inc. | 7.67 Million USD | 77.86% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 69.133% |
| ONE Bio Corp. | 9.04 Million USD | 81.214% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 86.882% |
| Mesoblast Limited | 55.85 Million USD | 96.96% |
| MultiCell Technologies, Inc. | 90.04 USD | -1886045.047% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 94.442% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.16% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -172.876% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -68.528% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 58.76% |
| Biomind Labs Inc. | 711.4 Thousand USD | -138.724% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 15.06% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 86.739% |
| Skye Bioscience, Inc. | -5.72 Million USD | 129.683% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -372.126% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 24.042% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -1114.761% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -1161.362% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 69.933% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -8448.271% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 331.381% |
| EV Biologics, Inc. | 1.36 Million USD | -24.146% |
| Q BioMed Inc. | 4.06 Million USD | 58.17% |
| GB Sciences, Inc. | 1.74 Million USD | 2.806% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 1024.046% |
| CSL Limited | 10.52 Billion USD | 99.984% |
| Agentix Corp. | 37.63 Thousand USD | -4412.995% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 97.195% |
| Enzolytics Inc. | 981.65 Thousand USD | -73.002% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 6.45 Million USD | 73.674% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 352.312% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 22.875% |
| argenx SE | -2.02 Billion USD | 100.084% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 96.09% |
| HST Global, Inc. | 96.79 Thousand USD | -1654.554% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 103.612% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -723.543% |
| Halberd Corporation | 144.72 Thousand USD | -1073.489% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 75.982% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 119.212% |
| Zenith Capital Corp. | 10.06 Thousand USD | -16774.851% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 37.301% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 28.824% |
| AVAX Technologies, Inc. | -5.9 Million USD | 128.769% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -932.336% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 9371.127% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -747.312% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.17 Million USD | 22.042% |
| Helix BioMedix, Inc. | -2.57 Million USD | 166.08% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 91.624% |
| Kadimastem Ltd | -253.1 Thousand USD | 770.988% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | 62.024% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -743.852% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 129740.076% |
| LadRx Corporation | -2.03 Million USD | 183.394% |
| Cell Source, Inc. | 9.23 Million USD | 81.604% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 8421.663% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -167.376% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -167.376% |
| Affymax, Inc. | -5.59 Million USD | 130.343% |
| Mobile Lads Corp. | 484.23 Thousand USD | -250.717% |
| Itoco Inc. | 228.3 Thousand USD | -643.867% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -1148.84% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 65.74% |
| International Stem Cell Corporation | 2.59 Million USD | 34.429% |
| CytoDyn Inc. | 20.26 Million USD | 91.618% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 262586.09% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 18423.508% |
| Qrons Inc. | 351.42 Thousand USD | -383.254% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 77.962% |
| SYBLEU INC | 473.71 Thousand USD | -258.504% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 780.348% |
| Rebus Holdings, Inc. | 305 Thousand USD | -456.815% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 61.896% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -2621.044% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 22.129% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 50.545% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 80.144% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -119.812% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 235.863% |
| Neutra Corp. | 52.18 Thousand USD | -3154.23% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 168.232% |
| PureTech Health plc | -167.19 Million USD | 101.016% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 793.438% |
| IXICO plc | -4.44 Million USD | 138.21% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 87.153% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 96.904% |
| CSL Limited | 10.52 Billion USD | 99.984% |
| Cellectis S.A. | -43.81 Million USD | 103.876% |